Vitrafy Life Sciences Limited has released a press release.
FY25 Appendix 4E and Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Vitrafy Life Sciences Ltd. on 6ix
In the deck
Story so far
Earlier from Vitrafy Life Sciences
- FY25 Full Year Results Presentation
- Leadership Transition at Vitrafy
- Q4 FY25 Quarterly Activities Report and Appendix 4C
- Q3 FY25 Quarterly Activities Report and Appendix 4C
- USAISR successful Phase 1 Blood Platelet study
Later from Vitrafy Life Sciences
- FY25 Full Year Results Presentation - Amended
- Q1 FY26 Quarterly Activities Report and Appendix 4C
- IMV Strategic Partnership Investor Presentation
- Vitrafy Enters Strategic Commercial Agreement with IMV
- Q2 FY26 Quarterly Activities Report and Appendix 4C
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences